Table 1:
Clinical characteristics of patients with mRCC with and without thromboembolic complications.
| Characteristics, n (%) | TE (N=42) | No TE (N=328) | p-value |
|---|---|---|---|
| Age, median (95% CI), y | 64 (60–66) | 61.5 (60–63) | 0.19 |
| Male | 35 (83) | 225 (68) | 0.05 |
| BMI, median (95% CI) | 30.44 (27.50–34.15) | 27.99 (27.01–28.86) | 0.09 |
| Race | |||
| White | 35 (88) | 285 (90) | 0.59 |
| Black/African American | 0 | 2 (0.6) | |
| Hispanic/Latino | 4 (10) | 18 (5.6) | |
| Asian/Pacific Islander | 1 (2) | 9 (2.8) | |
| Native American | 0 | 3 (1) | |
| Nephrectomy | 34 (83) | 267 (81) | 1.00 |
| Fuhrman Grade | |||
| <=2 | 8 (24) | 58 (24) | 1.00 |
| >2 | 25 (76) | 182 (76) | |
| clear cell RCC | 30 (90) | 258 (78) | 0.07 |
| IMDC risk classification | |||
| Favorable | 0 | 43 (14) | 0.01 |
| Intermediate | 24 (73) | 174 (59) | 0.74 |
| Poor | 9 (27) | 80 (27) | 0.85 |
| Synchronous metastasis | 13 (31) | 140 (43) | 0.15 |
| Karnofsky PS <80 | 6 (17) | 53 (17) | 1.00 |
| Chronic kidney disease | 8 (23) | 84 (28) | 0.69 |
| Anemia | 25 (68) | 188 (61) | 0.48 |
| Neutrophilia | 6 (17) | 62 (18) | 0.82 |
| Hypercalcemia | 4 (11) | 20 (7) | 0.31 |
| Thrombocytosis | 5 (14) | 55 (18) | 0.65 |